* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Days Payable falls into.
Sun Pharma Advanced Research Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (NSE:SPARC) has a Days Payable of 1,108.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sun Pharma Advanced Research Co and its competitors. This is 387% above median its historical median of 227.54. Over the past decade, Sun Pharma Advanced Research Co's Days Payable has ranged from 169.90 to 847.69. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #33 out of 922 companies in the Drug Manufacturers industry, placing it in the top 3.6%.
Is Sun Pharma Advanced Research Co's Days Payable too high?
Sun Pharma Advanced Research Co's current Days Payable of 1,108.12 is 387% above median its 10-year median of 227.54. Over the past 10 years, this metric has ranged from a low of 169.90 to a high of 847.69. The Drug Manufacturers industry median Days Payable is 90.84. Sun Pharma Advanced Research Co's value of 1,108.12 is 1119.9% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #33 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #33 out of 922 companies for Days Payable. This places Sun Pharma Advanced Research Co in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Sun Pharma Advanced Research Co's value of 1,108.12 is 1119.9% above this benchmark. Historically, Sun Pharma Advanced Research Co's own Days Payable has ranged from 169.90 to 847.69 over the past decade. While the company's 10-year median is 227.54 vs. the industry median of 90.84, Sun Pharma Advanced Research Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current Days Payable of 1,108.12 is 1119.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current Days Payable is 1,108.12, which is 387% above median its own 10-year median of 227.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,504.88, compared to a current price of ₹239.37 — trading 94.7% below its estimated fair value. The current Days Payable is 1,108.12, which is 387% above median its 10-year median of 227.54 and 1119.9% above the Drug Manufacturers industry median of 90.84. Sun Pharma Advanced Research Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Days Payable is 1,108.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued.
The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,504.88.
GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.
Key valuation signals for NSE:SPARC:
Days Payable: 1,108.12 (387% above median its 10-year median of 227.54)
GF Value™: ₹4,504.88 vs. price of ₹239.37 (94.7% below fair value)
Industry Position: 1119.9% above the Drug Manufacturers median (#33 of 922)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
61GF Score
Get the complete analysis for NSE:SPARC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
